A Multi Center Open Label Study to Assess the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel

Inclusion Criteria:

- The subject must give signed informed consent before any study-related activities.

- The partner, if applicable, must give signed informed consent before administration
of Somatuline Autogel.

- The subject must be able to understand the protocol requirements.

- The subject must have a clinical diagnosis of acromegaly due to pituitary tumor.

- The subject must be treated with a long-acting somatostatin analogue with or without
a dopamine agonist and have been on the current medical regimen for at least 3 months
prior to screening and have IGF-1 levels no higher than 10% above the upper limit of
the normal range for age and gender at the screening visit or be somatostatin
analogue naïve (if the subject is treated with a dopamine agonist he/she must have
been on the current dose for at least 3 months prior to screening).

- Subjects who are treated with a dopamine agonist have to stay on their current dose
for the duration of the study.

- Switch subjects must have had their last pre-study routine clinical treatment with
Sandostatin LAR between 28 and 35 days before Visit 2 (enrollment).

- The subject must be able to store the study medication in a refrigerator in his/her
own or his/her partner's home.

- The subject must be ≥18 years of age.

- Female subjects of childbearing potential must use adequate contraception.

- Female subjects of childbearing potential who are taking oral contraceptives must
agree to stay on their current contraceptive dose for the duration of the study.

- The partner, if applicable, must be ≥18 years of age.

Exclusion Criteria:

- The subject has had pituitary surgery (adenomectomy) within 3 months prior to
screening.

- The subject has received pituitary radiotherapy within 3 years prior to screening.

- The subject has received a GH receptor antagonist within 6 months prior to screening.

- The subject is currently on a higher dose of Sandostatin LAR than 30mg q28d

- The subject is pregnant or breastfeeding.

- The subject has clinically significant renal or hepatic abnormalities.

- The subject has a symptomatic, untreated biliary lithiasis.

- The subject has uncontrolled diabetes or thyroid disease.

- The subject has a known hypersensitivity to any of the test materials or related
compounds.

- The subject is unable or unwilling to comply with the protocol.

- The subject has received any investigational drug within 30 days prior to screening.

- The subject has participated in a medical device study within 30 days prior to
screening.

- The subject has previously participated in this study.